Myoinositol may be a factor in uremic immune deficiency

Area of Science:

• Immunology
• Nephrology
• Biochemistry

Background:

• Chronic kidney disease (CKD) is associated with impaired immune function, known as uremic immune deficiency.
• Elevated myoinositol levels are observed in the blood serum of patients undergoing regular hemodialysis.

Purpose of the Study:

• To investigate the in vitro effect of myoinositol on immune cell proliferation and antigen expression in chronic uremic patients and healthy subjects.
• To determine if high myoinositol concentrations contribute to uremic immune deficiency.

Main Methods:

• Assessing phytohemagglutinin (PHA)- and phorbol 12-myristate 13-acetate (PMA)-induced proliferation of peripheral blood mononuclear cells (PBMNCs) and T-cell enriched lymphocytes.
• Measuring the expression of CD3, CD4, CD8, and HLA-DR antigens on PHA-activated PBMNCs.
• Comparing responses in the presence of physiological (30 mumol/l) and uremic (600 mumol/l) myoinositol concentrations.

Main Results:

• High myoinositol (600 mumol/l) impaired PHA-induced PBMNC and T-cell proliferation, but not PMA-induced proliferation.
• Uremic myoinositol concentrations reduced CD3, CD4, and HLA-DR expression on PHA-activated PBMNCs.
• Normal myoinositol concentrations (30 mumol/l) did not affect immune cell responses.

Conclusions:

• Elevated myoinositol levels in uremic patients may inhibit PHA-induced immune cell proliferation through a mechanism involving the cell membrane.
• Myoinositol at uremic concentrations significantly depresses key immune antigen expression, potentially contributing to uremic immune deficiency.